AirSculpt Technologies, Inc.

What they do

AirSculpt performs proprietary, minimally invasive fat removal and skin tightening procedures (e.g., Power BBL, Up a Cup, Hip Flip) and offers fat transfer procedures. The company also introduced AirSculpt+ and AirSculpt Smooth for skin tightening and cellulite reduction, respectively. Operations are conducted through Professional Associations that handle clinical aspects and subsidiaries providing management services under MSAs. In 2025, the company performed 11,852 body contouring procedures.

Revenue drivers

• Body contouring procedures — Primary revenue source; 3,376 cases in Q2 2026 and 6,458 in H1 2026. Revenue per case was $12,707 in Q2 2026.
• Revenue per case — Q2 2026 revenue per case declined 2.1% to $12,707; H1 2026 was $12,742, down 1.2% from prior year.
• Same-center sales — Same-center case volume grew 1.0% in Q2 2026 and 1.1% YTD; same-center sales were stable (flat YTD).
• New procedures and partnerships — Exclusive partnership with AlloClae to offer an injectable adipose matrix, expected to broaden addressable patient population and expand revenue opportunities.

Recent performance

Revenue declined 3% in Q2 2026 to $42.9 million (from $44.0 million) and 1.3% in H1 2026 to $82.3 million (from $83.4 million). Net loss for Q2 2026 was $1.1 million versus a $0.6 million loss in Q2 2025; H1 net loss was $3.5 million versus $3.4 million. Adjusted EBITDA was $4.9 million in Q2 and $8.2 million in H1, down from $5.8 million and $9.6 million, respectively. Case volume was nearly flat: 3,376 cases in Q2 (down 0.5%) and 6,458 in H1 (down 0.2%). The company cited stable same-center sales for the second consecutive quarter.

Strategy

Management is prioritizing stability and growth: increasing marketing investment, expanding the procedure mix (including the AlloClae partnership), and improving financial flexibility by reducing gross debt and increasing cash. Debt reduction of $30 million since start of 2025 to $44.2 million, and cash increased by $10 million to $18.8 million. The company also amended its term loan to extend maturity to November 2027, with required payments of $2.5 million at signing and another $2.5 million by September 30, 2026, plus 50% of future equity proceeds to prepay debt.

Risks

• Revenue decline — Revenue decreased 15.8% in 2025 to $151.8 million, and Q2 2026 revenue fell 3% year-over-year, indicating ongoing demand pressure.
• Competition from weight-loss drugs — The company faces increased competition from GLP-1 and other weight-loss drugs, which may reduce demand for surgical body contouring procedures.
• Macroeconomic headwinds — Inflation and rising interest rates could adversely affect consumer spending on elective procedures and increase operating costs.
• Same-center performance risk — If same-center case and revenue growth does not stabilize, the company's financial results and growth strategy could be harmed.

Outlook

Management reaffirmed full-year 2026 revenue guidance at the lower end of $151 to $157 million. Adjusted EBITDA outlook was reduced to $12 to $14 million. The company expects to continue investing in marketing and new procedures, while managing debt and liquidity, including the amended term loan maturity extension to November 2027.